CRISPR Therapeutics AG (CRSP.O): Casgevy Beats Cons, SCD Franchise Poised for Profitability In 2027. 2H26 Readouts Pave Way For 2027 Ph3. $88 TP (+$6)

Research evidence excerpt

CRISPR Therapeutics AG (CRSP.O): Casgevy Beats Cons, SCD Franchise Poised for Profitability In 2027. 2H26 Readouts Pave Way For 2027 Ph3. $88 TP (+$6)

CRISPR Therapeutics AG (CRSP.O)

03 August 2026 Citi Research

securities in the Republic of China (Taiwan). The Product is for informational purposes only and is not intended as an offer or

solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products

mentioned in the Product must take into account existing public information on such security or the financial products or any

registered prospectus.

The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and

Exchange Commission of Thailand. 399 Interchange 21 Building, 18th Floor, Sukhumvit Road, Klongtoey Nua, Wattana

,Bangkok 10110, Thailand.

Disclosure for investors in the Republic of Turkey: The Product is made available in Turkey through Citibank AS which is

regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey.

Under Capital Markets Law of Turkey (Law No: 6362), the investment information, comments and recommendations stated

here, are not within the scope of investment advisory activity. Comments and recommendations stated here rely on the

individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial

status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated

here may not bring about outcomes that fit your expectations. Furthermore, Citi Research is a division of Citigroup Global

Markets Inc.